AMGEN Inc.

NASDAQ: AMGN    
Share price (3/27/24): $286.30    
Market cap (3/27/24): $153 billion
20 AMGEN Inc. Expert Interviews, now on BamSEC.
 Powered by Tegus.

Material Contracts Filter

EX-10.22 5
from 10-K 3 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Both (I) Is Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Such Excluded Information Has Been Marked With “[***]”
12/34/56
EX-10.17 1
from 10-K 6 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Such Excluded Information Has Been Marked With “[*]”
12/34/56
EX-10.17
from 10-K 248 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Such Excluded Information Has Been Marked With “[*]”. Collaboration and Licence Agreement Between AMGEN Inc. and Celltech R&D Limited Re Beer Beer Collaboration and Licence Agreement I N De X
12/34/56
EX-10.14
from 10-K 7 pages Agreement Between Amgen Inc. and James Bradner
12/34/56
EX-10.12 4
from 10-K 1 page Fourth Amendment to the AMGEN Nonqualified Deferred Compensation Plan as Amended and Restated Effective October 16, 2013
12/34/56
EX-10.9 5
from 10-K 1 page Fifth Amendment to the AMGEN Inc. Supplemental Retirement Plan as Amended and Restated Effective October 16, 2013
12/34/56
EX-10.6
from 10-K 7 pages AMGEN Inc. 2009 Director Equity Incentive Program (Effective January 1, 2024 (The “Effective Date”)) as Amended and Restated October 24, 2023
12/34/56
EX-10.5
from 10-K 34 pages Form of Award Notice
12/34/56
EX-10.3
from 10-K 36 pages Form of Award Notice
12/34/56
EX-10.2
from 10-K 37 pages Form of Award Notice
12/34/56
EX-10.20 2
from 10-Q 10 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Second Amendment to Collaboration Agreement
12/34/56
EX-10.11 4
from 10-K 1 page Fourth Amendment to the AMGEN Inc. Supplemental Retirement Plan as Amended and Restated Effective October 16, 2013
12/34/56
EX-10.7
from 10-K 35 pages Form of Award Notice
12/34/56
EX-10.5
from 10-K 35 pages Form of Award Notice
12/34/56
EX-10.4
from 10-K 38 pages Form of Award Notice
12/34/56
EX-10.1
from 8-K 5 pages Amendment No. 3 to Share Purchase Agreement
12/34/56
EX-10.36
from 10-Q 16 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 1 to Agreement No. 00135085 Between AMGEN USA Inc. and Davita Inc
12/34/56
EX-10.47
from 10-Q 9 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 1 to the Collaboration Agreement Article 1 - Amendment
12/34/56
EX-10.46
from 10-Q 107 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Collaboration Agreement by and Between AMGEN Inc. and Astrazeneca Collaboration Ventures, LLC
12/34/56
EX-10.41
from 10-Q 6 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. First Amendment to Collaboration Agreement
12/34/56